21.99 USD
+0.48 (+2.23%)
At close: Feb 6, 2026
21.99 USD
0 (0%)
After Hours: 2/6/2026, 8:01:20 PM
PRVA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. PRVA has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, PRVA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year PRVA was profitable.
- In the past year PRVA had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: PRVA reported negative net income in multiple years.
- PRVA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of PRVA (1.34%) is comparable to the rest of the industry.
- The Return On Equity of PRVA (2.56%) is comparable to the rest of the industry.
- Looking at the Return On Invested Capital, with a value of 2.45%, PRVA is in line with its industry, outperforming 48.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 2.56% | ||
| ROIC | 2.45% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 0.89%, PRVA is in line with its industry, outperforming 53.92% of the companies in the same industry.
- PRVA's Profit Margin has declined in the last couple of years.
- PRVA has a Operating Margin (1.38%) which is in line with its industry peers.
- In the last couple of years the Operating Margin of PRVA has declined.
- With a Gross Margin value of 10.17%, PRVA is not doing good in the industry: 73.53% of the companies in the same industry are doing better.
- PRVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.38% | ||
| PM (TTM) | 0.89% | ||
| GM | 10.17% |
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PRVA is destroying value.
- The number of shares outstanding for PRVA has been increased compared to 1 year ago.
- Compared to 5 years ago, PRVA has more shares outstanding
- PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- PRVA has an Altman-Z score of 4.28. This indicates that PRVA is financially healthy and has little risk of bankruptcy at the moment.
- PRVA has a better Altman-Z score (4.28) than 78.43% of its industry peers.
- There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.28 |
ROIC/WACC0.28
WACC8.86%
2.3 Liquidity
- PRVA has a Current Ratio of 1.67. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
- PRVA's Current ratio of 1.67 is fine compared to the rest of the industry. PRVA outperforms 63.73% of its industry peers.
- PRVA has a Quick Ratio of 1.67. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 1.67, PRVA is in the better half of the industry, outperforming 68.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.67 | ||
| Quick Ratio | 1.67 |
3. Growth
3.1 Past
- PRVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.00%, which is quite impressive.
- PRVA shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.43% yearly.
- The Revenue has grown by 19.01% in the past year. This is quite good.
- PRVA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.17% yearly.
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%66.67%
Revenue 1Y (TTM)19.01%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%27.1%
3.2 Future
- Based on estimates for the next years, PRVA will show a very strong growth in Earnings Per Share. The EPS will grow by 59.93% on average per year.
- The Revenue is expected to grow by 2.73% on average over the next years.
EPS Next Y22%
EPS Next 2Y71.06%
EPS Next 3Y59.93%
EPS Next 5YN/A
Revenue Next Year-27.71%
Revenue Next 2Y-9.42%
Revenue Next 3Y-3.6%
Revenue Next 5Y2.73%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 169.15, PRVA can be considered very expensive at the moment.
- PRVA's Price/Earnings ratio is in line with the industry average.
- The average S&P500 Price/Earnings ratio is at 27.93. PRVA is valued rather expensively when compared to this.
- With a Price/Forward Earnings ratio of 68.32, PRVA can be considered very expensive at the moment.
- PRVA's Price/Forward Earnings is on the same level as the industry average.
- PRVA's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.77.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 169.15 | ||
| Fwd PE | 68.32 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, PRVA is valued a bit more expensive than the industry average as 60.78% of the companies are valued more cheaply.
- Based on the Price/Free Cash Flow ratio, PRVA is valued a bit cheaper than the industry average as 60.78% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.43 | ||
| EV/EBITDA | 60.7 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PRVA does not grow enough to justify the current Price/Earnings ratio.
- PRVA's earnings are expected to grow with 59.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)7.69
PEG (5Y)22.75
EPS Next 2Y71.06%
EPS Next 3Y59.93%
5. Dividend
5.1 Amount
- No dividends for PRVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
21.99
+0.48 (+2.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-26 2026-02-26/amc
Inst Owners98.68%
Inst Owner Change-1.25%
Ins Owners1.85%
Ins Owner Change0%
Market Cap2.70B
Revenue(TTM)2.04B
Net Income(TTM)18.17M
Analysts84.44
Price Target32.15 (46.2%)
Short Float %2.23%
Short Ratio3.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-34.97%
Min EPS beat(2)-60.96%
Max EPS beat(2)-8.97%
EPS beat(4)0
Avg EPS beat(4)-37.14%
Min EPS beat(4)-60.96%
Max EPS beat(4)-8.97%
EPS beat(8)0
Avg EPS beat(8)-42.01%
EPS beat(12)3
Avg EPS beat(12)40.52%
EPS beat(16)6
Avg EPS beat(16)56.54%
Revenue beat(2)2
Avg Revenue beat(2)11.82%
Min Revenue beat(2)5.73%
Max Revenue beat(2)17.91%
Revenue beat(4)4
Avg Revenue beat(4)8.08%
Min Revenue beat(4)0.75%
Max Revenue beat(4)17.91%
Revenue beat(8)8
Avg Revenue beat(8)5.39%
Revenue beat(12)10
Avg Revenue beat(12)0.33%
Revenue beat(16)10
Avg Revenue beat(16)-9.08%
PT rev (1m)-0.08%
PT rev (3m)-0.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-44.24%
EPS NY rev (1m)0%
EPS NY rev (3m)-20.77%
Revenue NQ rev (1m)-28.53%
Revenue NQ rev (3m)-22.59%
Revenue NY rev (1m)-39.9%
Revenue NY rev (3m)-37.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 169.15 | ||
| Fwd PE | 68.32 | ||
| P/S | 1.32 | ||
| P/FCF | 24.43 | ||
| P/OCF | 24.43 | ||
| P/B | 3.81 | ||
| P/tB | 7.32 | ||
| EV/EBITDA | 60.7 |
EPS(TTM)0.13
EY0.59%
EPS(NY)0.32
Fwd EY1.46%
FCF(TTM)0.9
FCFY4.09%
OCF(TTM)0.9
OCFY4.09%
SpS16.61
BVpS5.77
TBVpS3
PEG (NY)7.69
PEG (5Y)22.75
Graham Number4.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 2.56% | ||
| ROCE | 3.67% | ||
| ROIC | 2.45% | ||
| ROICexc | 5.77% | ||
| ROICexgc | N/A | ||
| OM | 1.38% | ||
| PM (TTM) | 0.89% | ||
| GM | 10.17% | ||
| FCFM | 5.42% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-10.22%
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
F-Score7
Asset Turnover1.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 112.37 | ||
| Cash Conversion | 296.89% | ||
| Profit Quality | 609.36% | ||
| Current Ratio | 1.67 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 4.28 |
F-Score7
WACC8.86%
ROIC/WACC0.28
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%66.67%
EPS Next Y22%
EPS Next 2Y71.06%
EPS Next 3Y59.93%
EPS Next 5YN/A
Revenue 1Y (TTM)19.01%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%27.1%
Revenue Next Year-27.71%
Revenue Next 2Y-9.42%
Revenue Next 3Y-3.6%
Revenue Next 5Y2.73%
EBIT growth 1Y114.42%
EBIT growth 3YN/A
EBIT growth 5Y1.07%
EBIT Next Year573.42%
EBIT Next 3Y111.21%
EBIT Next 5Y64.24%
FCF growth 1Y142.02%
FCF growth 3Y26.09%
FCF growth 5Y42.42%
OCF growth 1Y141.5%
OCF growth 3Y25.67%
OCF growth 5Y35.01%
PRIVIA HEALTH GROUP INC / PRVA FAQ
What is the fundamental rating for PRVA stock?
ChartMill assigns a fundamental rating of 4 / 10 to PRVA.
Can you provide the valuation status for PRIVIA HEALTH GROUP INC?
ChartMill assigns a valuation rating of 2 / 10 to PRIVIA HEALTH GROUP INC (PRVA). This can be considered as Overvalued.
Can you provide the profitability details for PRIVIA HEALTH GROUP INC?
PRIVIA HEALTH GROUP INC (PRVA) has a profitability rating of 3 / 10.
Can you provide the PE and PB ratios for PRVA stock?
The Price/Earnings (PE) ratio for PRIVIA HEALTH GROUP INC (PRVA) is 169.15 and the Price/Book (PB) ratio is 3.81.
Can you provide the financial health for PRVA stock?
The financial health rating of PRIVIA HEALTH GROUP INC (PRVA) is 7 / 10.